Trial Profile
The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2020
Price :
$35
*
At a glance
- Drugs Cobicistat (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOLBI
- 09 Nov 2019 Results assessing the effect of switching to dolutegravir-based dual therapy on body composition and factors associated with these changes published in the AIDS
- 31 Oct 2018 Results (n=102) assessing the safety and efficacy of the dual regimen of dolutegravir plus rilpivirine in patients with toxicity or drug-drug interactions, presented at the 14th International Congress on Drug Therapy and HIV Infection.
- 29 Jun 2018 Status changed from recruiting to completed.